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Abstract 
Background: Artemisinin resistance in Plasmodium falciparum has emerged as a major threat for malaria control 
and elimination worldwide. Mutations in the Kelch propeller domain of PfK13 are the only known molecular mark-
ers for artemisinin resistance in this parasite. Over 100 non-synonymous mutations have been identified in PfK13 
from various malaria endemic regions. This study aimed to investigate the genetic diversity of PvK12, the Plasmodium 
vivax ortholog of PfK13, in parasite populations from Southeast Asia, where artemisinin resistance in P. falciparum has 
emerged.
Methods: The PvK12 sequences in 120 P. vivax isolates collected from Thailand (22), Myanmar (32) and China (66) 
between 2004 and 2008 were obtained and 353 PvK12 sequences from worldwide populations were retrieved for 
further analysis.
Results: These PvK12 sequences revealed a very low level of genetic diversity (π = 0.00003) with only three single 
nucleotide polymorphisms (SNPs). Of these three SNPs, only G581R is nonsynonymous. The synonymous mutation 
S88S is present in 3% (1/32) of the Myanmar samples, while G704G and G581R are present in 1.5% (1/66) and 3% 
(2/66) of the samples from China, respectively. None of the mutations observed in the P. vivax samples were associ-
ated with artemisinin resistance in P. falciparum. Furthermore, analysis of 473 PvK12 sequences from twelve worldwide 
P. vivax populations confirmed the very limited polymorphism in this gene and detected only five distinct haplotypes.
Conclusions: The PvK12 sequences from global P. vivax populations displayed very limited genetic diversity indicat-
ing low levels of baseline polymorphisms of PvK12 in these areas.
Keywords: Artemisinin resistance, Kelch domain protein, Plasmodium vivax, Malaria, Genetic diversity, PfK13, PvK12
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria is a major public health problem in the Greater 
Mekong Subregion (GMS), including Cambodia, China, 
Laos, Myanmar, Thailand, and Vietnam [1]. Malaria in 
these GMS countries is concentrated along the inter-
national borders. Since 2001, artemisinin (ART) com-
bination therapy (ACT) has been recommended as the 
first-line treatment in the national treatment guidelines 
of most malaria endemic countries and have played an 
important role in reducing global malaria-associated 
mortality and morbidity. However, the recent emergence 
of ART resistance in Plasmodium falciparum in the GMS 
is extremely concerning. P. falciparum isolates resist-
ant to ARTs were first detected in this region in 2008 [2]. 
Since then, ART resistance has spread and/or emerged in 
other areas of the GMS [3–6]. ART resistance is defined 
as the parasite clearance half-life of >5 h or presence of 
parasites in patients 3 days after ART treatment. Recently, 
mutations in the propeller domain of the Kelch 13 (K13) 
gene from P. falciparum (PF3D7_1343700) were shown 
to be associated with in vitro resistance to ART as well as 
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in vivo delayed parasite clearance [7]. Kelch-like proteins 
consist of a series of four to seven Kelch motifs which 
interact with different binding partners, thereby mediat-
ing a wide variety of cellular functions [8]. Some Kelch 
proteins also act as substrate adaptors for the cullin 3 
ubiquitin ligases [9], but their exact functions in Plasmo-
dium remain to be elucidated. In a transcriptomics study, 
Mok et  al. have shown that the parasites with mutated 
K13 have an upregulated unfolded protein response 
pathway [10]. Another study has shown that ART acts 
via the parasite’s cell stress response involving the ubiq-
uitin/proteasome system, which is enhanced by certain 
k13 mutations [11]. Furthermore, phosphatidylinositol-
3-kinase (PI3K)-mediated signaling has been identified 
as a probable target of ART, and K13 has been shown to 
regulate the levels of PI3K in parasites [12]. More studies 
are required in order to delineate the underlying molecu-
lar mechanism of K13-mediated ART resistance. Follow-
ing the identification of k13 gene as a molecular marker 
for ART resistance [7, 13], numerous studies have been 
performed to assess the polymorphism in this gene from 
various malaria endemic regions [14–21]. Several muta-
tions in the Kelch propeller domain have now been asso-
ciated with in vitro ring-stage survival assays and delayed 
parasite clearance rates in patients treated with ARTs 
[7, 13, 22]. Consequently, sequencing the Kelch propel-
ler domain of the k13 gene has become an important tool 
in the surveillance of ART resistance in P. falciparum. A 
total of 186 k13 alleles, including 108 nonsynonymous 
mutations, have been reported so far in P. falciparum 
[23]. There is significant geographic heterogeneity in both 
the patterns of the k13 mutations and their prevalence 
across the GMS [23], possibly reflecting different drug 
histories and evolutionary origins. Fortunately, the resist-
ance associated mutations are still confined to Southeast 
Asia. Some rare alleles are found in other regions but are 
not associated with ART resistance [23–26].
While P. falciparum is responsible for the majority of 
malaria-related mortality, Plasmodium vivax is the most 
prevalent parasite species outside of Africa. Plasmodium 
vivax caused an estimated 13.8 million cases globally in 
2015, and accounted for about half of all malaria cases 
outside Africa [27]. Although chloroquine (CQ) remains 
the primary treatment option for P. vivax, ACT is used 
in places such as Indonesia where CQ resistance is evi-
dent in this parasite [28]. To date, there are no reports 
of clinical resistance of P. vivax to ARTs. Yet, in areas 
with co-endemicity of P. falciparum and P. vivax, mixed 
infections often occur at high prevalence [29]. ACT is 
also used to treat mixed-species infections [30, 31]. As a 
result, P. vivax may have been under similar drug selec-
tive pressure as P. falciparum. For example, point muta-
tions in pvdhfr and copy number variations in pvmdr1 
may reflect past drug histories of pyrimethamine and 
mefloquine, respectively, which have been used to treat 
falciparum malaria [32–34]. Therefore, it would be inter-
esting to determine whether ART drugs have imposed 
similar selection on PvK12 gene. PvK12 is the ortholog 
of the PfK13, and is present on chromosome 12 of P. 
vivax [35]. A recent study showed that a nonsynony-
mous mutation in the PvK12 gene circulates at very low 
frequencies in Cambodia where ART resistance in P. fal-
ciparum first emerged [35]. Thus, this study aims to char-
acterize the baseline genetic variability of PvK12 gene in 
parasite populations from various regions in the GMS 
collected in 2004–2008, before the first reports of ART 
resistance in P. falciparum.
Methods
Collection of Plasmodium vivax clinical samples
Clinical P. vivax samples were collected from patients 
with acute P. vivax malaria in central China (66), north-
east Myanmar (32) and western Thailand (22) in 2004–
2008. Diagnosis was conducted by microscopy and 
finger-prick blood samples from confirmed P. vivax 
patients were blotted onto Whatman filter papers. 
Since central China is only endemic for P. vivax malaria 
and treatment has always been CQ-primaquine, para-
site population from this region would have never been 
exposed to ART drugs. These parasite samples would be 
controls for the baseline mutations in the PvK12 gene. In 
Thailand, artesunate has been used since 1990s mostly 
in combination with mefloquine [36, 37], whereas at the 
China–Myanmar border, ART family drugs began to be 
deployed in late 1970s mostly as monotherapies until 
2005. Therefore, P. vivax parasites from Thailand and 
northeast Myanmar are expected to have been exposed 
to ART drugs since mixed-species infections were 
deemed relatively prevalent in these areas [29].
Sequencing of P. vivax K12 gene
Parasite genomic DNA was isolated from the dried 
blood spots using the QiaAmp DNA Mini Kit (Qiagen, 
Germany) according to the manufacturer’s instructions. 
The extracted DNA was eluted in 30  μl of TE buffer 
(10  mM Tris–HCl, 0.1  M EDTA, pH 8.0) and stored at 
−20  °C until use. A nested PCR approach was designed 
to amplify the full-length PvK12 gene (Fig.  1) using the 
primers shown in Additional file 1. Primary PCR ampli-
fication was performed with a 25  μl reaction mixture 
containing 1  μl of gDNA, 0.2  µM each primer, 2.5  mM 
MgCl2, and 0.3 µl Advantage® 2 DNA polymerase (Clon-
tech, Japan) under the following conditions: 94  °C for 
2 min, followed by 35 cycles at 94  °C for 20 s, 62  °C for 
30 s, and 65 °C for 2 min, and a final extension at 65 °C 
for 5  min. Nested PCR amplifications were performed 
Page 3 of 10Wang et al. Malar J  (2016) 15:537 
Fig. 1 Domain organization and conservation of K13 protein across different Plasmodium species. a The PvK12 gene is shown in red. P1F and P1R 
shows the primer set used for the primary PCR. P2F and P2R shows the primers used for nested PCR for the amplification of full length PvK12. All the 
amplification primers used are present outside the ORF. SPF1, SPR1, SPF2, SPR2, SPF3, SPR3, SPF4 and SPR4 show the primers used for sequencing.  
b Schematic domain organization of Kelch protein in each species showing the BTB domain and six Kelch domains. The numbers of cysteine 
residues in each Kelch domain is indicated. Additional Tho2 and Cdc_37 N kinase binding domains are also shown. c Percentage of sequence 
similarity between amino acid sequences of seven Plasmodium species. d Neighbor-Joining tree of Kelch protein amino acid sequences from seven 
Plasmodium species. Bootstrap values generated from 1000 replicates are shown
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in a 25 μl reaction mixture with 1 μl of the primary PCR 
product, 0.2 µM each primer, 2.5 mM MgCl2, and 0.3 μl 
Advantage® 2 DNA polymerase under the following con-
ditions: 94  °C for 2  min, followed by 35 cycles at 94  °C 
for 20 s, 60° C for 30 s, and 65 °C for 2 min, and a final 
extension at 65  °C for 5  min. The amplified PCR prod-
ucts were detected on a 1% agarose gel, and the sizes of 
the PCR products were estimated based on a 1 kb DNA 
ladder (NEB, USA). All PCR products were purified with 
the QIAquick Gel Extraction Kit (Qiagen, Germany) fol-
lowed by sequencing in both directions using sequenc-
ing primers shown in Additional file  1. Sequences were 
assembled using Vector NTI (Invitrogen, USA) with 
manual editing.
Phylogeny of PfK13 orthologs
Orthologs of PfK13 from other malaria parasite species 
P. vivax (PVX_083080); Plasmodium reichenowi 
(PRCDC_1342700); Plasmodium chabaudi (PCHAS_ 
1361300); Plasmodium berghei (PBANKA_1356700); 
Plasmodium yoelii (PY17X_1362400); Plasmodium 
knowlesi (PKNH_1257700); and Plasmodium cynomolgi 
(PCYB_122000) were retrieved from PlasmoDB [38]. 
Sequences were aligned using CLUSTALW with manual 
editing. All the analyses in this study were done using 
MEGA6. A phylogenetic tree was constructed using the 
Neighbour-Joining method with 1000 pseudo-replica-
tions. Domain organization of PfK13 orthologs were ana-
lysed by using Batch CD-search tool in NCBI database, 
with E value cut off 0.10 [39].
Kelch protein genetic diversity
To understand the global distribution of diversity in the 
PvK12 gene, 353 published sequences were retrieved 
from PlasmoDB, including Cambodia (n  =  284) [35], 
Thailand (n = 14), China (n = 5), North Korea (n = 1), 
Columbia (n = 22), Mexico (n = 10), Peru (n = 10), India 
(n = 2), Papua New Guinea (n = 3), Brazil (n = 1) and 
Mauritania (n  =  1) (Additional file  2). All sequences 
were aligned against the Sal-1 reference sequence 
(PVX_083080) using MEGA6 [40]. Mutation in the 
PvK12 protein was mapped to the PvK12 protein 3-D 
structure predicted by using the I-TASSER online pro-
tein structure prediction tool [41] with the PfK13 pro-
tein structure as the template (ProteinDataBank:4YY8). 
Nucleotide diversity (π) and haplotype diversity (Hd) 
of PvK12 were determined by MEGA 6. The number of 
haplotypes was estimated from all the isolates and the 
Median-Joining method in NETWORK v4.6.1.3 program 
(fluxus-engineering.com) was used to establish genetic 
relationship among the PvK12 haplotypes [42].
Natural selection and tests of neutrality
The rates of synonymous (dS) and nonsynonymous (dN) 
mutations were estimated using the modified Nei and 
Gojobori method [43] and significance was compared 
by the Z-test (P < 0.05). Tajima’s D [44] was determined 
using DnaSP 5.10.00, which tests the departure from the 
neutral theory of evolution with the assumption that 
the population size was constant. Significantly posi-
tive Tajima’s D values indicate a recent population bot-
tleneck or balancing selection, whereas negative values 
suggest population expansion or directional selection. 
McDonald–Kreitman (MK) test, which compares the 
ratio of non-synonymous to synonymous substitutions 
(dN/dS) with polymorphic difference (within species; 
KS) and fixed difference (between closely related spe-
cies; Ka) was used to examine the departure from neu-
trality using either P. knowlesi (PkK12) or P. cynomolgi 
(PcyK12) ortholog as the outgroup [45]. A sliding win-
dow approach was also used to identify specific regions 
of PvK12 that deviate from neutral expectations using a 
window size of 10 and a step size of 5 bp.
Results
Conservation of the Kelch proteins across different 
Plasmodium species
Kelch proteins are a widespread group of proteins that 
contain multiple Kelch motifs that form a β-propeller 
tertiary structure. These Kelch-β-propellers are gener-
ally involved in protein–protein interactions. In Plas-
modium, the PfK13 orthologs also contain a BTB/POZ 
(Broad-Complex, Tramtrack, and Bric-a-Brac/Poxvi-
rus and Zinc finger) domain in addition to the multiple 
Kelch motifs (Fig. 1b). Interestingly, there are two other 
conserved functional domains present in some of these 
Plasmodium orthologs (Fig. 1b; Additional file 3). Kelch 
proteins of P. vivax, P. berghei, P. chabaudi, P. cynomolgi, 
P. knowlesi, and P. yoelii have the Tho2-like (transcrip-
tion factor/nuclear export subunit protein 2) domain. 
THO domain-containing proteins (in complex with other 
proteins) have function in messenger ribonucleoprotein 
metabolism and play a role in preventing transcription-
associated genetic instability [46, 47]. Furthermore, in P. 
berghei and P. chabaudi, a Cdc37_N terminal kinase bind-
ing domain is also present (Fig. 1b). Cdc37 is a molecular 
chaperone required for the activity of numerous eukar-
yotic protein kinases, and this domain is present in the 
heat shock protein 70 (hsp 70) protein of P. falciparum. 
Alignment of Tho2 and Cdc37  N domains with respec-
tive conserved domain protein families is shown in 
Additional file  3. The full-length K13 protein sequences 
from the eight Plasmodium species vary from 712 to 
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738 aa (Fig. 1b). To estimate the evolutionary history of 
Kelch proteins among different Plasmodium species, the 
PfK13 orthologs from P. vivax, P. berghei, P. chabaudi, P. 
cynomolgi, P. knowlesi, P. reichenowi and P. yoelii were 
used for analysis. These proteins are evolutionarily con-
served among the different Plasmodium species with 
high sequence similarity. Alignment of these eight Kelch 
proteins showed that both the BTB and Kelch domains 
are highly conserved (Additional file  4). The sequence 
similarity was the highest between P. falciparum and P. 
reichenowi (99.72%), and lowest between P. falciparum 
and P. chabaudi (84.68%) (Fig.  1c). Phylogenetic tree 
generated from eight Kelch protein sequences revealed 
three monophyletic branches, which conforms to earlier 
report of the phylogeny of the Plasmodium group based 
on other genetic markers [48]. The three rodent parasites 
grouped together, while P. falciparum was clustered with 
P. reichenowi. The other three species P. vivax, P. cyn-
omolgi and P. knowlesi were branched together (Fig. 1d).
The Plasmodium Kelch protein shows homology with 
the human KEAP1 protein. KEAP1 is a substrate adaptor 
protein for an ubiquitin ligase complex that targets the Nrf2 
transcription factor for degradation [49]. C151, C273, and 
C288 in the KEAP1 protein have been shown to be crucial 
for its interaction with Nrf2 in humans [50]. C151 lies in the 
BTB domain, while C273 and C288 lie in the linker region 
between BTB and Kelch domains of KEAP1 (Additional 
file 5). Alignment of Human KEAP1 with PvK12 shows that 
these cysteine residues are not conserved in the Plasmo-
dium Kelch proteins (Additional file 5). In Plasmodium, the 
6–8 cysteine residues are present only in the Kelch domains 
and are conserved across the different Plasmodium species 
(Fig. 1b; Additional file 4).
Genetic diversity of PvK12 in P. vivax isolates 
from Southeast Asia
The full-length PvK12 gene from 120 P. vivax isolates 
from Southeast Asia including Thailand (22), Myanmar 
(32) and central China (66) collected between 2004 and 
2008 was amplified and sequenced. The full-length open 
reading frame (ORF) of PvK12 is 2139  bp encoding 712 
amino acids (aa). Three mutations were observed in the 
samples when compared to the Sal-I reference sequence. 
Out of these mutations only one was nonsynonymous that 
resulted in an amino acid change (G581R). G581R and 
the synonymous mutation G704G were both found in the 
samples from China in 1.5% (1/66) and 3% (2/66) isolates 
respectively, whereas the other synonymous mutation 
S88S was present in one of the 32 samples from Myanmar. 
No mutations were identified in the Thai samples. The 120 
parasite samples exhibited a very low level of genetic diver-
sity (π < 0.00004) (Table 1). The G581R mutation lies in the 
propeller region of PvK12 protein (Fig. 2). The two synon-
ymous mutations are present outside the Kelch domains. 
None of the mutations observed in these samples have 
been associated with ART resistance in P. falciparum.
Worldwide population genetic diversity of PvK12
Tajima’s D test performed on 473 PvK12 sequences 
obtained in the world did not detect potential natural 
selection on this gene (Table  1). In isolates from China, 
Myanmar and Cambodia, the Tajima’s D values were 
negative, suggesting the occurrence of rare alleles at low 
frequencies in these populations. Moreover, in these 
populations dN was significantly lower than dS, giving 
rise to negative ‘dN-dS’ values. MK test was used for com-
paring interspecific divergence (Ka/KS) using sequences 
from two phylogenetically related species P. cynomolgi 
and P. knowlesi. Ka/Ks ratio of >1 indicates positive selec-
tion, whereas Ka/Ks ratio between 0 and 1 shows neu-
tral or disadvantageous mutations. A sliding window for 
Ka/Ks obtained by comparing the P. vivax sequences to 
sequences of P. cynomolgi and P. knowlesi gave Ka/Ks val-
ues of <0.5 in the full-length PvK12 protein indicating the 
absence of selection in this protein (Fig. 3). The Ka/Ks val-
ues were slightly higher in the N-terminal region before 
the BTB domain and the C-terminus after the Kelch 
domain, as compared to the rest of the protein. Further, 
the third Kelch motif has Ka/Ks values ranging between 
0.1 and 0.2 when compared to P. knowlesi, whereas it is 
Table 1 Single nucleotide polymorphisms and summary statistics of PvK12 in different geographical regions (n number 
of isolates, s number of SNPs, H haplotypes, Hd haplotype diversity, Ns number of non-synonymous, Ss number of syn-
onymous
n s H π θ Hd Ns Ss Tajima’s D dN-dS
China 66 2 3 0.00004 0.00020 0.089 1 1 −1.31509 −0.9
Thailand 22 0 1 0.00000 0.00000 0.000 0 0 NA 0
Myanmar 32 1 2 0.00003 0.00012 0.063 0 1 −1.14244 −1.1
Cambodia 284 1 2 0.0000065 0.000075 0.014 1 0 −0.87436 1.1
Others 69 0 1 0.00000 0.00000 0.000 0 0 NA 0
Total 473 4 5 0.00001 0.00028 0.025 2 2 −1.52620 −1.0
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close to zero in the rest of protein sequence. This again 
confirms that the BTB and Kelch domains are highly con-
served across different Plasmodium species.
To evaluate the population division of the worldwide P. 
vivax populations based on PvK12, the 120 sequences from 
this study were analysed along with 353 available PvK12 
sequences from twelve global P. vivax populations, includ-
ing sequences from five Asian (Thailand, China, Myan-
mar, Cambodia, India and North Korea), three American 
(Peru, Mexico, Columbia) and one African (Mauritania) 
countries. Genetic differentiation between worldwide 
populations was assessed by the haplotype network analy-
sis (Additional file  6). Only five distinct haplotypes were 
observed including the wild type as the predominant. 
These haplotypes appear to have emerged independently in 
the Asian populations at very low frequencies as evidenced 
by the haplotype network (Additional file 6).
Discussion
Anti-malarial drugs used to treat falciparum malaria 
have a significant impact on sympatric Plasmodium spe-
cies, such as P. vivax, which is the second major cause 
of malaria in humans. As no reliable molecular markers 
associated with P. vivax drug resistance have been identi-
fied yet, it remains difficult to assess the antimalarial drug 
resistance of P. vivax from clinical studies. Therefore, it 
is important to identify drug resistance markers that 
can be used to determine the emergence and spread of 
resistance in P. vivax. The primary treatment for P. vivax 
consists of two drugs CQ and primaquine; but resistance 
to CQ was reported in many endemic areas [28]. In the 
sample collection areas of this study, CQ/primaquine 
remains as the primary treatment of vivax malaria with 
high efficacy. There were only sporadic reports of clini-
cal CQ resistance in P. vivax in western Thailand [51] and 
the Thai–Myanmar border [52], though recent studies in 
northeast Myanmar suggested deteriorating CQ efficacy 
for treatment of P. vivax malaria [53].
The Kelch family proteins in Plasmodium consist of six 
conserved Kelch motifs and the BTB domain. The Plas-
modium Kelch proteins are highly conserved across dif-
ferent species and are most similar to the human KEAP1 
protein which is the major upstream regulator of a tran-
scription factor (Nrf2) in humans [49]. KEAP1 binds the 
Cullin3 ubiquitin ligase via its N-terminal BTB domain 
and central linker domain, while the C-terminal Kelch 
domain of KEAP1 binds to Nrf2 [54]. Upon exposure to 
oxidative stress, ubiquitination of Nrf2 is inhibited that 
leads to the increased transcription of cytoprotective 
antioxidant responsive elements dependent genes [55]. 
Furthermore, C151, C273, and C288 in human KEAP1 
have been shown to be important for Nrf2 ubiquitination 
[50]. To investigate whether malaria parasites employ a 
similar molecular mechanism, we aligned KEAP1 pro-
tein sequence from humans with PvK12 which revealed 
that these Cys residues are not conserved in Plasmodium 
(Additional file 5), while 6–8 conserved Cys residues are 
present in the Kelch domain in the malaria parasite. In 
addition the conserved domain analysis showed the pres-
ence of Tho2 domain and the Cdc37_N terminal kinase 
Fig. 2 Structure modelling of Plasmodium vivax K12 propeller domain. 3D model of the six propeller blades was predicted by the I-TASSER software 
using the PfK13 protein structure as the template (Protein Data Bank: 4YY8). The non-synonymous mutation G581R is highlighted in red and lies in 
the third blade of the β-propeller domain
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binding domain in some of the Plasmodium Kelch pro-
tein orthologs (Fig.  1b; Additional file  3). THO domain 
containing proteins function in mRNA transcription, 
processing and nuclear export of spliced mRNAs [56], 
whereas Cdc37_N terminal kinase binding domain acts 
as a molecular chaperone essential for the function of 
numerous eukaryotic protein kinases [57]. It would be 
interesting to unravel the cellular functions of the Kelch 
proteins with such domains in the malaria parasites.
Reports from the GMS have associated mutations in 
the propeller domain of PfK13 with ART resistance. 
According to a previous report by Popovici et al. PvK12 
polymorphism in Cambodia was very limited compared 
to that of the P. falciparum K13 gene. Only 2 out of the 
284 samples had the same nonsynonymous mutation at 
codon 552 (V552I) in samples from 2013 [35]. The cur-
rent study tried to determine the genetic polymorphism 
in full-length PvK12 sequences from 120 P. vivax clinical 
isolates from China, Thailand and Myanmar collected in 
2004–2008. The V552I mutation was not detected, while 
two synonymous (S88S, G704G) and one nonsynony-
mous (G581R) mutations were identified in these sam-
ples. All mutations were present at very low prevalence: 
S88S in 3% Myanmar samples, G704G in 1.5% China 
samples, and G581R in 3% China samples. Interestingly, 
though the G581R mutation drastically changes the prop-
erty of the residue, it corresponds to the G595S mutation 
reported in PfK13 in P. falciparum samples from Mali 
[58], which has not been associated with ART resistance. 
Since there is no clinical outcome or resistance pheno-
type information for the P. vivax isolates, it is not clear 
whether the G581R mutation has any functional signifi-
cance. It should be pointed out that the G581R mutation 
were present only in the central China samples, where 
ART drugs have never been used since this region is only 
endemic for vivax malaria. Therefore, without clinical 
resistance of P. vivax parasites to ART drugs, the point 
mutations observed in the world P. vivax populations 
Fig. 3 Within- and between-species divergence of PvK12. Sliding window analysis of Ka/Ks (non-synonymous divergence/synonymous divergence) 
calculated between P. vivax (PVX_083080) versus P. knowlesi (PKNH_1257700); P. cynomolgi (PCYB_122000). Window size of 10 bp and step size of 
5 bp were used
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could well represent background mutations. This finding 
is consistent with the low-level baseline mutations identi-
fied by Mita et al. in P. falciparum populations before the 
deployment of ACT [59].
In agreement with a previous report from Cambodia 
[35], the current results also showed limited baseline 
sequence diversity in PvK12 in additional GMS countries. 
Further analysis using a total of 473 PvK12 sequences 
from twelve worldwide P. vivax populations from 2001 
to 2013 confirmed a very low level of genetic diversity as 
compared to that of the PfK13 gene. This result implies 
that PvK12 sequences from these areas are highly con-
served with very low level of baseline polymorphisms. 
Since our samples used were collected in 2004–2008, it 
is necessary to conduct follow-up studies using parasite 
samples collected in more recent years in these regions 
such as Indonesia where intensive deployment of ACT 
for the treatment of vivax malaria has occurred.
Conclusions
Analysis of these samples along with 473 PvK12 
sequences from twelve worldwide P. vivax populations 
collected in 2001–2013, revealed a low baseline level of 
PvK12 polymorphisms.
Additional files
Additional file 1: Table S1. Primers used for amplification and sequenc-
ing of the full-length PvK12 gene.
Additional file 2: Table S2. Accession numbers of Plasmodium vivax 
Kelch protein K12 (Pv K12) sequences retrieved from Plasmodb.
Additional file 3. Alignment of the Tho2 and Cdc37 N domains. Align-
ment of the Tho2 and Cdc37 N domains of Plasmodium with the THo2 
and Cdc37 N conserved domain family proteins. The hyphens show the 
gaps in the alignment.
Additional file 4. Multiple sequence alignment of Kelch protein from 
seven different Plasmodium species. Clustal Omega server was used 
to align the Kelch proteins from P. falciparum (PF3D7_1343700); P. 
reichenowi (PRCDC_1342700); P. chabaudi (PCHAS_1361300); P. berghei 
(PBANKA_1356700); P. yoelii (PY17X_1362400); P. knowlesi (PKNH_1257700); 
P. cynomolgi (PCYB_122000), P. vivax (PVX_083080). The BTB and the Kelch 
domains are boxed in red and blue respectively. Cysteine residues are 
highlighted in green. The dots indicate the break in the sequences. The 
BTB domains starting from 327 are shown and boxed in red. The Kelch 
domains are shown in blue box. The hyphens show the gaps in the 
alignment.
Additional file 5. Alignment of PvK12 with human KEAP1. The BTB and 
Kelch domains are boxed for both the proteins. The Pvk12 BTB domain is 
boxed in blue and Kelch domain in green; the human KEAP1 BTB domain 
is boxed in red and Kelch domain in pink, respectively. All the cysteines 
are highlighted in red. C151, C273, C288 of KEAP1 are highlighted in yel-
low. The hyphens show the gaps in the alignment.
Additional file 6. Haplotype network for PvK12 from global P. vivax 
populations. The size of the pies reflects the frequency of a particular 
haplotype. The lengths of the lines connecting the pies, measured from 
their centres, are in proportion to the number of base pair substitutions 
separating the haplotypes. Color represents different countries. (H1: 
GGGA; H2: GAGA; H3: GGAA; H4: GGGG; H5: AGGA). Right panel shows the 
five haplotypes with their frequency in 473 P. vivax isolates.
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